Posted On: 12/21/2015 9:32:01 PM
Post# of 72447
The primary asset of that "whole company" was Daptomycin. I seem to recall that the over $1 billion in revenue being brought in by Daptomycin accounted for well over 80% of the company's total revenue. Further, the other revenue producing drugs were declining in sales and the drugs in the Cubist development pipeline were somewhat questionable.
It is a fact that Merck paid $9.5 billion for a company who's most valuable asset (by far) was Daptomycin.
It is a fact that Merck paid $9.5 billion for a company who's most valuable asset (by far) was Daptomycin.
Quote:
"Go read the post I am replying to; I'm not the one who brought up Trius acquisition. You're wrong that Cubist sold Cubicin to Merck for $9B. It was the whole company that was acquired and it's not just Cubicin that was sold. There were other antibiotics that were inherited from that acquisition and that includes Zerbaxa and Sivextro (originally from Trius), hence that's why the whole acquisition was worth $9B." - lousy engineer
(0)
(0)
